Alprazolam inhalation - Engage Therapeutics
Alternative Names: AZ-002; FNP-002; Staccato® alprazolam; STAP-001; UCB 7538Latest Information Update: 28 Jun 2024
At a glance
- Originator Alexza Pharmaceuticals
- Developer Alexza Pharmaceuticals; Engage Therapeutics; UCB Biopharma
- Class Antiepileptic drugs; Anxiolytics; Azoles; Benzodiazepines; Hypnosedatives; Small molecules
- Mechanism of Action GABA A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Epilepsy
- No development reported Asthma
- Discontinued Panic disorder
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for phase-I development in Asthma in USA (Inhalation)
- 28 May 2024 No recent reports of development identified for phase-I development in Epilepsy(In adolescents, Treatment-experienced) in USA (Inhalation, Powder)
- 13 Apr 2024 Efficacy and adverse event data from a phase I trial in Asthma presented at 76th Annual Meeting of the American Academy of Neurology 2024 (AAN-2024)